| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10040476 | Archives of Medical Research | 2005 | 14 Pages |
Abstract
Currently there are no antimalarial drugs targeted to stop the nuclear transcription process, a vital event for all replication stages of P. falciparum. Due to its absolute requirement in transcription initiation, we consider the pfTBP-pfTFIIB interface as a new potential target for novel antimalarial chemotypes.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Jacob BuendÃa-Orozco, Adán Guerrero, Nina Pastor,